Oklo stock tumbles as Financial Times scrutinizes valuation
Investing.com - H.C. Wainwright raised its price target on Tarsus Pharmaceuticals (NASDAQ:TARS) to $88.00 from $72.00 on Monday, while maintaining a Buy rating on the stock. The company, currently valued at $3.08 billion, has seen its shares surge nearly 100% over the past year, according to InvestingPro data.
The price target increase comes ahead of earnings and reflects positive sentiment toward the ongoing XDEMVY launch, with the firm adjusting market penetration projections to align with the demonstrated trajectory of drug sales.
H.C. Wainwright noted that XDEMVY sales have shown quarterly growth ranging from approximately 18% to 31% throughout 2025, which it believes can be sustained in the near term based on current commercial initiatives.
The firm increased its revenue estimates based on expansion of the prescriber base, with over 20,000 eye care professionals now writing prescriptions for XDEMVY, and raised its peak estimated 2036 market penetration from 20% to 25%.
H.C. Wainwright’s updated sales estimates and higher price target reflect its continued conviction in the XDEMVY launch trajectory.
In other recent news, Tarsus Pharmaceuticals reported its earnings for the second quarter of 2025, revealing notable financial results. The company achieved a revenue of $102.7 million, surpassing analysts’ forecasts of $95.68 million. However, the earnings per share (EPS) fell short of expectations, coming in at -$0.48 compared to the anticipated -$0.38. Despite the miss in EPS, the revenue beat contributed to a positive market response. Analysts have noted that the strong revenue performance, coupled with optimistic forward guidance, has played a significant role in investor sentiment. These developments highlight the company’s current financial trajectory and provide insights into its recent performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.